Tuesday, June 27, 2023 5:52:14 PM
I do not see this as being “discombobulated”. With the further explanation and color, it is pretty straight-forward and clear.
Also, I do not see any “inexplicable delays”. I believe that is a false narrative, created by some, all across social media platforms, and used to create angst and impatience among NWBO longs.
NWBio is doing some things that have never been done before. They are trial-blazing paths that have not been travelled before. They are strategically handling BLA / MAA submissions in the US, Canada, UK, Germany and the rest of the EU.
They are on the brink of changing the way solid tumor cancer patients are treated worldwide. Starting with newly diagnosed and recurrent GBM patients. They are developing a platform treatment for all or most solid tumor cancers.
This investment is not for everyone. Especially investors who are very impatient, or who do not believe in the NWBio management team, or the DCVax science and data, or who thinks these things are easy and should happen fast.
Also, I do not see any “inexplicable delays”. I believe that is a false narrative, created by some, all across social media platforms, and used to create angst and impatience among NWBO longs.
NWBio is doing some things that have never been done before. They are trial-blazing paths that have not been travelled before. They are strategically handling BLA / MAA submissions in the US, Canada, UK, Germany and the rest of the EU.
They are on the brink of changing the way solid tumor cancer patients are treated worldwide. Starting with newly diagnosed and recurrent GBM patients. They are developing a platform treatment for all or most solid tumor cancers.
This investment is not for everyone. Especially investors who are very impatient, or who do not believe in the NWBio management team, or the DCVax science and data, or who thinks these things are easy and should happen fast.
Bullish
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
